{"id":390,"date":"2020-03-19T20:00:53","date_gmt":"2020-03-19T20:00:53","guid":{"rendered":"http:\/\/mcpg.org.my\/v1\/?page_id=390"},"modified":"2020-03-19T20:14:19","modified_gmt":"2020-03-19T20:14:19","slug":"good-pharmaceutical-trading-practices-gptp","status":"publish","type":"page","link":"https:\/\/mcpg.org.my\/v1\/elements\/pages\/good-pharmaceutical-trading-practices-gptp\/","title":{"rendered":"Good Pharmaceutical Trading Practices (GPTP)"},"content":{"rendered":"\n\n  <div class=\"banner has-hover has-parallax\" id=\"banner-879178907\">\n          <div class=\"banner-inner fill\">\n        <div class=\"banner-bg fill\" data-parallax=\"-3\" data-parallax-container=\".banner\" data-parallax-background>\n            <div class=\"bg fill bg-fill \"><\/div>\n                        <div class=\"overlay\"><\/div>            \n                    <\/div><!-- bg-layers -->\n        <div class=\"banner-layers container\">\n            <div class=\"fill banner-link\"><\/div>            \n\n   <div id=\"text-box-511001311\" class=\"text-box banner-layer x50 md-x50 lg-x50 y80 md-y80 lg-y80 res-text\">\n                                <div class=\"text dark\">\n              \n              <div class=\"text-inner text-center\">\n                  \n\n<h1 class=\"lead\">Good Pharmaceutical Trading Practices (GPTP) for Private Sector<\/h1>\n<p class=\"lead\">Learn how we overcome problems<\/p>\n\n              <\/div>\n           <\/div><!-- text-box-inner -->\n                            \n<style scope=\"scope\">\n\n#text-box-511001311 {\n  width: 100%;\n}\n#text-box-511001311 .text {\n  font-size: 100%;\n}\n<\/style>\n    <\/div><!-- text-box -->\n \n\n        <\/div><!-- .banner-layers -->\n      <\/div><!-- .banner-inner -->\n\n            \n<style scope=\"scope\">\n\n#banner-879178907 {\n  padding-top: 400px;\n}\n#banner-879178907 .bg.bg-loaded {\n  background-image: url(https:\/\/mcpg.org.my\/v1\/wp-content\/uploads\/2020\/03\/pharmacy_3315803b.jpg);\n}\n#banner-879178907 .overlay {\n  background-color: rgba(0, 0, 0, 0.49);\n}\n<\/style>\n  <\/div><!-- .banner -->\n\n\n<div class=\"row\"  id=\"row-1879509688\">\n\n<div class=\"col small-12 large-12\"  ><div class=\"col-inner\"  >\n\n<div class=\"container section-title-container\" ><h1 class=\"section-title section-title-bold-center\"><b><\/b><span class=\"section-title-main\" style=\"font-size:70%;color:rgb(6, 0, 95);\">Good Pharmaceutical Trading Practices (GPTP) for Private Sector<\/span><b><\/b><\/h1><\/div><!-- .section-title -->\n\n<p style=\"text-align: center;\"><span style=\"color: #000000;\">Good Pharmaceutical Trading Practices (GPTP) for Private Sector is a guideline initiated by Pharmacy\u00a0Service Department, Ministry of Health Malaysia. GPTP is seen to be governing the Trade Matters\u00a0under the Good Governance of Medicines (GGM), and also a guide to be followed to ensure the\u00a0nation to achieve its objectives of National Medicine Policy (Dunas).<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"color: #000000;\">MCPG has been actively involved all dialogues with the Pharmacy Service Department from the\u00a0beginning and glad that it was finally finalized and endorsed by the government in 2015. Not long\u00a0from that, an official reminder letter from the department has also been circulated out to all\u00a0stakeholders to ensure that this guideline to be followed. This GPTP Unit under MCPG is formed with\u00a0the objectives to follow up the practice of GPTP, as well as to liaise with all stakeholders for any\u00a0amendment from time to time to ensure the guideline remain relevant with the development of our\u00a0healthcare system.<\/span><\/p>\n<div class=\"row\"  id=\"row-1876019885\">\n\n<div class=\"col medium-6 small-12 large-6\"  ><div class=\"col-inner\" style=\"background-color:rgb(249, 249, 249);padding:10px 10px 10px 10px;\" >\n\n<h3><span style=\"color: #003366;\"><strong>Scope of products<\/strong><\/span><\/h3>\n<p><span style=\"color: #000000;\">GPTP applies for medicines in Group B and Group C as stated in Poison Act 1952.<br \/><\/span><span style=\"color: #000000;\">* Group B: Prescription Only Medicine (POM).<br \/><\/span><span style=\"color: #000000;\">* Group C: Pharmacist Only Medicinal Product (POMP).<br \/><\/span><span style=\"color: #000000;\">* Psychotropic substances, dangerous drugs and pseudoephedrine are excluded from this guideline.<\/span><\/p>\n\n<\/div><\/div>\n<div class=\"col medium-6 small-12 large-6\"  ><div class=\"col-inner\" style=\"background-color:rgb(249, 249, 249);padding:10px 10px 10px 10px;\" >\n\n<h3><span style=\"color: #003366;\"><strong>Distribution channels<\/strong><\/span><\/h3>\n<p><span style=\"color: #000000;\">GPTP covers all licensed pharmaceutical distribution channels including but not limited to\u00a0pharmacies, clinics, hospitals and wholesalers.<\/span><\/p>\n\n<\/div><\/div>\n\n<\/div>\n<h3><span style=\"color: #003366;\"><strong>Components<\/strong><\/span><\/h3>\n<p><span style=\"color: #000000;\">1. Standard price and bonus scheme to all channels and healthcare providers.<\/span><\/p>\n<p><span style=\"color: #000000;\">\u2022 All pharmaceutical companies shall extend the same bonus scheme to all distributing\u00a0channels.<br \/><\/span><span style=\"color: #000000;\">\u2022 Reasonable bonus scheme is allowed.<br \/><\/span><span style=\"color: #000000;\">\u2022 There should not be any inducement for purchase with extra gifts and benefits.<br \/><\/span><span style=\"color: #000000;\">\u2022 Accessibility of product shall not be impeded with trading terms such as additional charges,\u00a0listing fees and etc.<\/span><\/p>\n<p><span style=\"color: #000000;\">2. Provision of an official wholesale price list and formal announcement on price revision or any change of trading terms from the suppliers<\/span><\/p>\n<p><span style=\"color: #000000;\">\u2022 Formal notification from the company before any price revision should be sent to all\u00a0relevant distributing channels and MOH at least 1 month before the execution of new price.<br \/><\/span><span style=\"color: #000000;\">\u2022 Suppliers shall provide an official wholesale price list to MOH once a year.<\/span><\/p>\n<p><span style=\"color: #000000;\">3. There should not be any market exclusivity for a product to any channel unless advised or\u00a0directed by MOH.<\/span><\/p>\n<p><span style=\"color: #000000;\">\u2022 All products and their stock keeping unit (SKU) should be made available to all distributing\u00a0channels.<\/span><\/p>\n<p><span style=\"color: #000000;\">4. Promotion of products and services responsibly within the code of conduct\/ practices.<\/span><\/p>\n<p><span style=\"color: #000000;\">\u2022 All associations and guilds shall develop their own code of conduct\/ practices in line with the\u00a0MOH\u2019s guideline on good governance in medicine (has not developed yet).<\/span><\/p>\n<p><span style=\"color: #000000;\">5. Appropriate system of control and accountability of sample provided to healthcare\u00a0professional shall be established.<\/span><\/p>\n<p><span style=\"color: #000000;\">\u2022 Samples are not meant to be sold and resell.<br \/><\/span><span style=\"color: #000000;\">\u2022 Samples are only for newly launched medicines less than 2 years in market, unless justified.<br \/><\/span><span style=\"color: #000000;\">\u2022 Sample distribution by medical representatives shall be discouraged.<\/span><\/p>\n<p><span style=\"color: #000000;\">6. The industry shall have competent and ethical medical representatives.<\/span><\/p>\n<p><span style=\"color: #000000;\">\u2022 Industry association shall assist in developing and implementing the updated training\u00a0curriculum.<\/span><\/p>\n\n<\/div><\/div>\n<div class=\"col medium-6 small-12 large-6\"  ><div class=\"col-inner\" style=\"background-color:rgb(249, 249, 249);padding:10px 10px 10px 10px;\" >\n\n<h3><span style=\"color: #003366;\"><strong>Definitions<\/strong><\/span><\/h3>\n<p><span style=\"color: #000000;\">i. Licensed pharmaceutical distribution channels: Any registered distribution channels with appropriate license issued by MOH related to their\u00a0business.<\/span><\/p>\n<p><span style=\"color: #000000;\">ii. Reasonable bonus: 30% differences (MCPG has kept this option open after being briefed\u00a0that the practice is not feasible as it may increase the price of the medicines)<\/span><\/p>\n<p><span style=\"color: #000000;\">iii. Newly launched medicinal product: New product (new chemical entity and generic) marketed from the first date of commercial sales.<\/span><\/p>\n<p><span style=\"color: #000000;\">iv. Medical representatives: Qualified and trained personnel who provides insight scientific knowledge and\/ or sales of a product.<\/span><\/p>\n<p><span style=\"color: #000000;\">v. Unless advised or directed by MOH:<\/span><\/p>\n<p><span style=\"color: #000000;\">\u2022 it is case to case basis especially for highly specialized product or treatment e.g. HIV case.<br \/><\/span><span style=\"color: #000000;\">\u2022 packaging for special requirement.<br \/><\/span><span style=\"color: #000000;\">\u2022 to safeguard public health.<\/span><\/p>\n\n<\/div><\/div>\n<div class=\"col medium-6 small-12 large-6\"  ><div class=\"col-inner\" style=\"background-color:rgb(249, 249, 249);padding:10px 10px 10px 10px;\" >\n\n<h3><span style=\"color: #003366;\"><strong>Reporting Supply Chains for Not Adhering to GPTP to MCPG<\/strong><\/span><\/h3>\n<p><span style=\"color: #000000;\">Members who encountered or has the evidence of any supply chain under the scope of GPTP for not\u00a0adhering to the GPTP are encouraged to report the matter and provide the evidence and event\u00a0details to MCPG Council through this webpage.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>i. Mitigation<\/strong><br \/><\/span><span style=\"color: #000000;\">Upon receiving sufficient details of the report, the complainant will receive a Case ID for follow up.<\/span><\/p>\n<p><span style=\"color: #000000;\">MCPG shall first initial the mitigation process with the said supply chains to ensure they take the\u00a0corrective action to adhere the GPTP with official letter from them. All correspondence in this stage\u00a0will be made known to relevant officers from Ministry of Health, as well supply chains\u2019 overseas HQ.<\/span><\/p>\n<p><span style=\"color: #000000;\"><strong>ii. Reporting to Malaysia Pharmacy Council<\/strong><\/span><\/p>\n<p><span style=\"color: #000000;\">Upon failing to get any satisfactory action plan or response from the said supply chains in 7-business\u00a0day, or in the period of time agreed by the council members, the case shall be escalated to the\u00a0attention of the Malaysia Pharmacy Council.<\/span><\/p>\n<p><strong><span style=\"color: #000000;\">iii. Reporting to MyCC, Medias and International Bodies<\/span><\/strong><\/p>\n<p><span style=\"color: #000000;\">Upon failing to get any satisfactory action plan or response from the Malaysia Pharmacy Council, in\u00a0the period of time agreed by the council members, MCPG may decide to report to Malaysia\u00a0Competition Commission, MyCC, liaise with medias or respective international bodies. Council\u00a0members may decide to escalate the complaints to the Director General of Health or Prime\u00a0Minister\u2019s Department depends on the severity of the non-compliance of GPTP.<\/span><\/p>\n\n<\/div><\/div>\n\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":11,"parent":46,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-transparent-header-light.php","meta":{"footnotes":""},"class_list":["post-390","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/mcpg.org.my\/v1\/wp-json\/wp\/v2\/pages\/390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mcpg.org.my\/v1\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mcpg.org.my\/v1\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mcpg.org.my\/v1\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mcpg.org.my\/v1\/wp-json\/wp\/v2\/comments?post=390"}],"version-history":[{"count":7,"href":"https:\/\/mcpg.org.my\/v1\/wp-json\/wp\/v2\/pages\/390\/revisions"}],"predecessor-version":[{"id":400,"href":"https:\/\/mcpg.org.my\/v1\/wp-json\/wp\/v2\/pages\/390\/revisions\/400"}],"up":[{"embeddable":true,"href":"https:\/\/mcpg.org.my\/v1\/wp-json\/wp\/v2\/pages\/46"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mcpg.org.my\/v1\/wp-json\/wp\/v2\/media\/11"}],"wp:attachment":[{"href":"https:\/\/mcpg.org.my\/v1\/wp-json\/wp\/v2\/media?parent=390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}